Better Therapeutics, Inc.
BTTX
$0.0002
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.44% | -10.69% | -2.40% | -8.30% | 137.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.43% | -26.82% | -4.49% | -31.25% | 22.25% |
| Operating Income | 51.43% | 26.82% | 4.49% | 31.25% | -22.25% |
| Income Before Tax | 48.61% | 23.57% | 3.17% | 36.96% | 8.50% |
| Income Tax Expenses | 0.00% | -- | -- | 233.33% | -- |
| Earnings from Continuing Operations | 48.60% | 23.56% | 3.16% | 36.92% | 8.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.60% | 23.56% | 3.16% | 36.92% | 8.47% |
| EBIT | 51.43% | 26.82% | 4.49% | 31.25% | -22.25% |
| EBITDA | 56.32% | 30.40% | 5.90% | 31.22% | -21.64% |
| EPS Basic | 68.36% | 42.23% | 4.85% | 42.83% | 59.76% |
| Normalized Basic EPS | 68.38% | 42.24% | 4.85% | 47.73% | 58.47% |
| EPS Diluted | 68.36% | 42.23% | 4.85% | 42.83% | 59.76% |
| Normalized Diluted EPS | 68.38% | 42.24% | 4.85% | 47.73% | 58.47% |
| Average Basic Shares Outstanding | 62.47% | 32.31% | 1.77% | 20.62% | 120.34% |
| Average Diluted Shares Outstanding | 62.47% | 32.31% | 1.77% | 20.62% | 120.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
